Leal Therapeutics Announces $45 Million Financing to Progress Novel Therapies for Patients with Major Neurodegenerative and Neuropsychiatric Disorders
Summary
This latest financing round follows a previously disclosed $39 million financing.The proceeds will be used to advance Leals pipeline of antisense oligonucleotide (ASO) and small molecule therapeutics for patients with CNS disorders. "We are pleased to have the support from this leading group of both new and existing investors that share our vision for better therapeutics for people with neurodegenerative or neuropsychiatric disorders," said Asa Abeliovich, M.D., Ph.D., founder and chief executive officer of Leal. ""We look forward to supporting this world-class team with deep expertise and proven track record in CNS therapeutics," said John Gustofson, head of Chugai Venture Fund. To learn more, visit www.newpath.partners.Chugai Venture Fund is a pioneering investment firm focused on fostering innovation and driving transformative advances in the life sciences industry. By providing strategic funding, mentorship and access to resources, we aim to create a collaborative ecosystem that accelerates the development and commercialization of breakthrough therapies and medical solutions.